MTUS1 and neoplasm: Further studies will be necessary to investigate the feasibility of in vivo methods aimed at re-expressing ATIP3, or active truncated domains of the protein, by using tumor-targeted systemic delivery of nanocomplexes as recently reported for the tumor suppressor RB94 [32].